Optimised ChIP Protocols for qPCR and Sequencing
Chromatrap, a business unit of Porvair Sciences, has announced a new web page that brings together protocols developed using their proprietary solid state chromatin immunoprecipitation (ChIP) technology.
The new web page provides scientists with optimised ChIP methodologies for qPCR, high throughput qPCR, sequencing, high throughput sequencing and enzymatic chromatin shearing using Chromatrap kits.
Chromatrap is a ground-breaking technology that offers a quicker, easier and more efficient way of undertaking ChIP assays. Chromatrap kits for qPCR use revolutionary Chromatrap Protein-A or Protein-G spin columns which contain discs of an inert, porous polymer to which protein A/G has been covalently attached. During an assay, the chromatin/antibody complex is retained by the disc. Flushing with three buffers and an elution step are all that is required to obtain the DNA fragments of interest. Operating without the use of magnetic or agarose beads all but eliminates non-specific background and drastically reduces manual handling error and sample loss. Optimized elution buffer chemistry allows samples to be analysed directly in qPCR without the need for DNA clean up, further reducing sample loss.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...